Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Italfarmaco has entered into an agreement with Multicare for the regulatory approval and distribution of givinostat as a treatment for Duchenne muscular dystrophy in Brazil.MILAN, Italy, September 16,...
-
Entrada Therapeutics announces the recipients of its third annual DREAMS Grant Program.
-
CORAL GABLES, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
-
CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
-
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0...
-
VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a supportive care treatmentGuideline inclusion may raise clinical awareness of...
-
Entrada Therapeutics reports financial results for the second quarter ended June 30, 2025, and highlights recent business updates.
-
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of...
-
European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD)Designation is paving the way for safer long-term...
-
CORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...